498 related articles for article (PubMed ID: 31419130)
41. Brigatinib versus crizotinib for ALK-positive NSCLC.
Stirrups R
Lancet Oncol; 2018 Nov; 19(11):e585. PubMed ID: 30293790
[No Abstract] [Full Text] [Related]
42. Safety issues with the ALK inhibitors in the treatment of NSCLC: A systematic review.
Kassem L; Shohdy KS; Lasheen S; Abdel-Rahman O; Ali A; Abdel-Malek RR
Crit Rev Oncol Hematol; 2019 Feb; 134():56-64. PubMed ID: 30771874
[TBL] [Abstract][Full Text] [Related]
43. miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC.
Lai Y; Kacal M; Kanony M; Stukan I; Jatta K; Kis L; Norberg E; Vakifahmetoglu-Norberg H; Lewensohn R; Hydbring P; Ekman S
Biochem Biophys Res Commun; 2019 Apr; 511(2):260-265. PubMed ID: 30791979
[TBL] [Abstract][Full Text] [Related]
44. Effects of Treatment with Crizotinib on Non-small Cell Lung Carcinoma with ALK Translocation in the Czech Republic.
Miloš P; Jana S; Vítězslav K; Monika Š; Leona K; Jaromír R; Renata C; Markéta Č; Andrea B; Juraj K; Michal H; Milada Z; Marek K; Helena Č; Martin S
Klin Onkol; 2018; 31(3):207-212. PubMed ID: 30441974
[TBL] [Abstract][Full Text] [Related]
45. Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib.
Muller IB; De Langen AJ; Honeywell RJ; Giovannetti E; Peters GJ
Expert Rev Anticancer Ther; 2016; 16(2):147-57. PubMed ID: 26654422
[TBL] [Abstract][Full Text] [Related]
46. Cost Effectiveness of Ceritinib and Alectinib Versus Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-small-cell Lung Cancer.
Li H; Lai L; Wu B
Clin Drug Investig; 2020 Feb; 40(2):183-189. PubMed ID: 31820329
[TBL] [Abstract][Full Text] [Related]
47. Anaplastic lymphoma kinase inhibitors in brain metastases from ALK+ non-small cell lung cancer: hitting the target even in the CNS.
Klempner SJ; Ou SH
Chin Clin Oncol; 2015 Jun; 4(2):20. PubMed ID: 26112806
[TBL] [Abstract][Full Text] [Related]
48. Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase.
Huang WS; Liu S; Zou D; Thomas M; Wang Y; Zhou T; Romero J; Kohlmann A; Li F; Qi J; Cai L; Dwight TA; Xu Y; Xu R; Dodd R; Toms A; Parillon L; Lu X; Anjum R; Zhang S; Wang F; Keats J; Wardwell SD; Ning Y; Xu Q; Moran LE; Mohemmad QK; Jang HG; Clackson T; Narasimhan NI; Rivera VM; Zhu X; Dalgarno D; Shakespeare WC
J Med Chem; 2016 May; 59(10):4948-64. PubMed ID: 27144831
[TBL] [Abstract][Full Text] [Related]
49. Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases.
Tomasini P; Egea J; Souquet-Bressand M; Greillier L; Barlesi F
Ther Adv Respir Dis; 2019; 13():1753466619831906. PubMed ID: 30786826
[TBL] [Abstract][Full Text] [Related]
50. Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial.
Christopoulos P; Bozorgmehr F; Brückner L; Chung I; Krisam J; Schneider MA; Stenzinger A; Eickhoff R; Mueller DW; Thomas M
BMC Cancer; 2021 Jun; 21(1):743. PubMed ID: 34182952
[TBL] [Abstract][Full Text] [Related]
51. Diagnosis and Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer.
Arbour KC; Riely GJ
Hematol Oncol Clin North Am; 2017 Feb; 31(1):101-111. PubMed ID: 27912826
[TBL] [Abstract][Full Text] [Related]
52. EGFR and EML4-ALK Updated Therapies in Non-Small Cell Lung Cancer.
De Mello RA; Liu DJ; Aguiar PN; Tadokoro H
Recent Pat Anticancer Drug Discov; 2016; 11(4):393-400. PubMed ID: 27491402
[TBL] [Abstract][Full Text] [Related]
53. A Bayesian network meta-analysis regarding the comparative efficacy of therapeutics for ALK-positive, brain metastatic non-small cell lung cancer.
Zhao B; Han Y; Wang Y; Wang Y; Wang Y; Xing H; Dai C; Wang Y; Wang H; Ma W
Pharmacol Res; 2021 Dec; 174():105931. PubMed ID: 34626769
[TBL] [Abstract][Full Text] [Related]
54. Update of Diagnosis and Targeted Therapy for ALK
Wang QA; Chen HW; Wu RC; Wu CE
Curr Treat Options Oncol; 2023 Dec; 24(12):1683-1702. PubMed ID: 37938503
[TBL] [Abstract][Full Text] [Related]
55. Structure-based discovery of SIAIS001 as an oral bioavailability ALK degrader constructed from Alectinib.
Ren C; Sun N; Kong Y; Qu X; Liu H; Zhong H; Song X; Yang X; Jiang B
Eur J Med Chem; 2021 May; 217():113335. PubMed ID: 33751979
[TBL] [Abstract][Full Text] [Related]
56. Brigatinib for
Ali R; Arshad J; Palacio S; Mudad R
Drug Des Devel Ther; 2019; 13():569-580. PubMed ID: 30804663
[TBL] [Abstract][Full Text] [Related]
57. Ceritinib for Untreated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.
Claxton L; O'Connor J; Woolacott N; Wright K; Hodgson R
Pharmacoeconomics; 2019 May; 37(5):645-654. PubMed ID: 30298279
[TBL] [Abstract][Full Text] [Related]
58. Crizotinib for the treatment of patients with advanced non-small cell lung cancer.
Bowles DW; Weickhardt AJ; Doebele RC; Camidge DR; Jimeno A
Drugs Today (Barc); 2012 Apr; 48(4):271-82. PubMed ID: 22536569
[TBL] [Abstract][Full Text] [Related]
59. Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK).
Zhang C; Han XR; Yang X; Jiang B; Liu J; Xiong Y; Jin J
Eur J Med Chem; 2018 May; 151():304-314. PubMed ID: 29627725
[TBL] [Abstract][Full Text] [Related]
60. Drug resistance in ALK-positiveNon-small cell lungcancer patients.
Qian M; Zhu B; Wang X; Liebman M
Semin Cell Dev Biol; 2017 Apr; 64():150-157. PubMed ID: 27693505
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
